Wed, Oct 22, 2014, 5:57 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

ONYX Pharmaceuticals, Inc. Message Board

schramekm 59 posts  |  Last Activity: 7 hours ago Member since: May 30, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Dr Robinson to Capetown

    by aviditymaybe 8 hours ago
    schramekm schramekm 7 hours ago Flag

    Held in the convention center too.
    Geovax better be careful with all this traveling by Hariatt. It will be 1% of Market Cap spent pretty soon just on Travel expences. :) :) :)

  • From NIH article
    Wednesday, Sept. 3, 2014
    Skip Content Marketing Share this:submit to facebook Tweet it submit to reddit submit to StumbleUpon submit to Google +

    MEDIA AVAILABILITY
    NIH-Led Scientists Discover HIV Antibody that Binds to Novel Target on Virus

    Main Content Area​WHAT:
    An NIH-led team of scientists has discovered a new vulnerability in the armor of HIV that a vaccine, other preventive regimen or treatment could exploit. The site straddles two proteins, gp41 and gp120, that jut out of the virus and augments other known places where broadly neutralizing antibodies (bNAbs) bind to HIV. This newly identified site on the viral spike is where a new antibody found by the scientists in an HIV-infected person binds to the virus. Called 35O22, the antibody prevents 62 percent of known HIV strains from infecting cells in the laboratory and is extremely potent, meaning even a relatively small amount of it can neutralize the virus.

    Following their discoveries, the scientists found that 35O22-like antibodies were common in a group of HIV-infected people whose blood contained antibodies that potently neutralized a broad array of HIV strains. According to the researchers, this suggests that it might be easier for a vaccine to elicit 35O22 than some other known bNAbs, which are less common.

    Since 35O22 binds only to forms of the viral spike that closely resemble those that naturally appear on HIV, the scientists believe a vaccine that elicits 35O22-like antibodies would need to mimic the natural shape of the spike as closely as possible. This would require a different approach than that used in many previous experimental HIV vaccines, which have included just parts of the viral spike rather than a structure that looks like the entire native viral spike.

    In addition, the researchers report, the HIV strains that 35O22 neutralizes complement strains neutralized by other bNAbs. This suggests that eliciting or combining 35O22 with a few other bNAbs in a vaccine or

  • Reply to

    Was THAT A Fun Ride.??

    by mysportcraft Oct 21, 2014 11:27 AM
    schramekm schramekm Oct 21, 2014 12:56 PM Flag

    Must have been Sabby behind the run up. I'm surprised they didn't let it go higher as it must of been them selling SHORT shares, knowing they could replace them a few days later at .275 from geovax. And they wouldn't even have to file a 8K and change their % of ownership. It will be interesting to see if ownership percentage does change after exercising warrants. If not , it definatly was them.

    Must say they played me like a toy. With the volume and the NEW PRESS , I really thought some financing was going to come through, on at least ONE of the two ends. Oh well, disappointed and frustrated with them ( Geovax), as always...

  • Reply to

    Govx stopped trading

    by robbsbeach Oct 17, 2014 12:18 PM
    schramekm schramekm Oct 17, 2014 12:26 PM Flag

    Quoting system down, I believe

  • schramekm schramekm Oct 17, 2014 10:24 AM Flag

    Mourningstardotcom

    amoung a bunch of others repots emory university is a 14% shareholder in geovax in the institutional holders section.

  • Reply to

    Full Time Employees=6

    by shoenfield Oct 17, 2014 9:16 AM
    schramekm schramekm Oct 17, 2014 9:56 AM Flag

    read the website, government has invested 50 Million to date.

  • Reply to

    Emory/GOVX infectious disease Team in Tx

    by robbsbeach Oct 15, 2014 1:08 PM
    schramekm schramekm Oct 16, 2014 10:59 AM Flag

    Ya, that's what I thought...

  • Reply to

    Emory University & Geovax

    by tipota4906 Oct 16, 2014 7:45 AM
    schramekm schramekm Oct 16, 2014 10:11 AM Flag

    From Mourning star
    Equity Ownership GOVX

    Funds Institutions



    Name Ownership Trend
    Previous 8 Qtrs Shares Change % Total
    Shares Held % Total
    Assets Date

    Emory University Premium 3,550,378 -1,071,027 14.22 0 05/02/2014

    Sabby Management LLC Premium 2,765,500 2,765,500 11.08 0 05/02/2014

    Welch & Forbes LLC Premium 2,230,799 2,230,799 8.93 0 05/02/2014

    First City Capital Management, Inc. Premium 1,200 1,200 0 0 06/30/2014

    BBK Capital Partners, LLC Premium 20 0 0 0 06/30/2014

    Total: Top 5 institutions Premium 8,547,897 3,926,472 34.23


    Govx also licences some of their patents from Emory.

  • Reply to

    Govx now has a live Ebola patient

    by robbsbeach Oct 16, 2014 9:59 AM
    schramekm schramekm Oct 16, 2014 10:07 AM Flag

    Is that a quote? do you have a link ???

  • Reply to

    Emory/GOVX infectious disease Team in Tx

    by robbsbeach Oct 15, 2014 1:08 PM
    schramekm schramekm Oct 15, 2014 6:18 PM Flag

    Phil,
    Thanks,... Emory holding 3.5 MILLION shares as of May 2, 2014 and has NOT sold any since 2010

    Plus harriat holds in excess of 10 % plus the Welches and Forbes refrenced below.also... Total insiders apx 55% EMORY being an INSIDER

    Equity Ownership GOVX

    Funds Institutions

    Name Ownership Trend
    Previous 8 Qtrs Shares Change % Total
    Shares Held % Total
    Assets Date

    Emory University Premium 3,550,378 -1,071,027 14.22 0 05/02/2014

    Sabby Management LLC Premium 2,765,500 2,765,500 11.08 0 05/02/2014

    Welch & Forbes LLC Premium 2,230,799 2,230,799 8.93 0 05/02/2014

    First City Capital Management, Inc. Premium 1,200 1,200 0 0 06/30/2014

    BBK Capital Partners, LLC Premium 20 0 0 0 06/30/2014

    Total: Top 5 institutions Premium 8,547,897 3,926,472 34.23

  • Reply to

    Emory/GOVX infectious disease Team in Tx

    by robbsbeach Oct 15, 2014 1:08 PM
    schramekm schramekm Oct 15, 2014 5:54 PM Flag

    Emory did NOT dump, they are still in...they sold apx 5% a few years ago, to rebalance portfolio.

  • schramekm schramekm Oct 14, 2014 1:21 PM Flag

    I think it will pick up after lunch is over. We should close up... I don't mind all the new attention. Even though most came as flippers, some are seeing this is indeed undervalued, as we have known for a long time, and some may stay for the long haul and help with more exposure. good news expected soon , and NOT just on price or volume. But $$$ development too...

  • schramekm by schramekm Oct 12, 2014 8:06 PM Flag

    hariatt said, hepatitis and human papaloma vacines both use vlp's in the recent video. I wonder if the adno vector vaccines that were stopped ( 505 trial ) express vlp's ??? I don't think even the tyland trial did either, did it?

    here is a page from trends in biotech about vlp's

    •Human vaccines against three viruses employ recombinant virus-like particles (VLPs).
    •VLPs are excellent vaccine antigens because they faithfully mimic the native virions.
    •Post-purification reassembly of VLPs can improve antigenicity and vaccine efficacy.
    •Critical quality attributes of VLPs are assessed to guide vaccine production.

    Human vaccines against three viruses use recombinant virus-like particles (VLPs) as the antigen: hepatitis B virus, human papillomavirus, and hepatitis E virus. VLPs are excellent prophylactic vaccine antigens because they are self-assembling bionanoparticles (20 to 60 nm in diameter) that expose multiple epitopes on their surface and faithfully mimic the native virions. Here we summarize the long journey of these vaccines from bench to patients.

    I wonder why Fucci from NIH keeps dissing vlp's ??? Could that be the reason Domi left and came over to Geovax?

  • Reply to

    NIH and Dr. Fauci Passed on Geovax?

    by mortdove Oct 10, 2014 1:12 PM
    schramekm schramekm Oct 10, 2014 7:29 PM Flag

    Ya , how do we expect we will have a drug to take into trials within a week? I think the best we can expect is some type of partnership with an existing experimental Ebola drug to be married up with our delivery system, I think that was what Dodd was speaking about in the Blaze interview... us getting together with other companys and the CDC to figure the BEST way to attack this problem and save human lives. ( Btw if we did partner with any Ebola drug with our delivery and it went BAD, that would reflect bad on us. I don't think they will take just anything to TRY just to get noticed. It will be a calculated bet on our part , I would think.

    What I was also hoping for was just an announcement that NIH was granting xxx$$$ to Geovax to Develop a vaccine to be married to our delivery system. ( That was the 18 month time period they keep referring too).

    Hopefully all this Ebola stuff is NOT distracting NIH from the existing Aids funding comminment that we are hoping will get sent our way. That's the other PR we could still see.

    I know a PR stated NIH would decide by end of third quarter , but 10 days out is still not yet a dead issue on funding. Harriatt said if No 3M from Nih they will look to other sources to manufacture vaccine FOR the TRIAL...

    Anyway best we hope for is $$$$$$ for Ebola or $$$$$$$ for 2B or both.

  • schramekm schramekm Oct 10, 2014 12:57 PM Flag

    Ya , mostly in 100-400 share lots. ???

  • schramekm by schramekm Oct 9, 2014 8:43 PM Flag

    Ebola outbreak could cause NIH to hold or redirect any monies it had earmarked for aids research.

  • schramekm schramekm Oct 9, 2014 1:04 AM Flag

    I sure loved the exchange at 3 minutes. they have been working on a vaccine for years now, but we just entered the ebola arena , because we HAVE BEEN ABLE TO VALIDATE A PARTICULAR TECHNOLOGY PLATFORM in the HIV arena , that makes us believe it will be HIGHLY APPLICABLE in the class, and then enable us TO MOVE MUCH MORE QUICKLY.

    Along with the new website , I think they have a new PR person at the helm. Probally their idea on the WS also. They are doing a good job so far. Keep David on the circuit.

  • Reply to

    Shorts 58% ..Sabby is busy today

    by invest332007 Oct 7, 2014 5:29 PM
    schramekm schramekm Oct 8, 2014 10:24 AM Flag

    this is fro otcmarketsdotcon it gives actual short every 2 weeks.people more educated than I say this is the rel data that matters. W are now at our lowest ammnt in last 14 months.

    Short Sales
    Date Short Interest % Change Avg. Daily Share Volume Days to Cover Split New Issue
    Sept 15, 2014 5,905 -43.41 16,437 1.00 No No
    Aug 29, 2014 10,435 168.87 16,121 1.00 No No
    Aug 15, 2014 3,881 26.42 27,348 1.00 No No
    Jul 31, 2014 3,070 -53.38 35,557 1.00 No No
    Jul 15, 2014 6,585 100.00 64,488 1.00 No No
    Jun 30, 2014 0 -100.00 27,534 0.00 No No
    Jun 13, 2014 497 -93.91 30,071 1.00 No No
    May 30, 2014 8,165 -80.78 22,358 1.00 No No
    cant wait to see next 2 time periods...

  • Reply to

    Shorts 58% ..Sabby is busy today

    by invest332007 Oct 7, 2014 5:29 PM
    schramekm schramekm Oct 7, 2014 6:34 PM Flag

    Yesterday was the first time I ever saw a mistake like that, and I watch 2 stocks there on a daily basis.

  • schramekm schramekm Oct 7, 2014 11:00 AM Flag

    wonder what just happened. we were stuck at .38 576k shares

    now another 150K and .42 cents. and round table just ending as I type.

ONXX
124.700.00(0.00%)Sep 30 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.